Progen Industries Limited

Anticancer drug development company appoints scientific advisory board

Published in Oncology Business Week, April 3rd, 2005

Progen Industries Limited (PGLAF) announced the appointment of a new scientific advisory board (SAB) coinciding with advancement in the company's drug discovery efforts.

The company's in house drug discovery intellectual property portfolio has been built on over 10 years of extensive collaborative academic research related to the role of heparan sulfate, a complex sugar implicated in several disease processes.

The primary objective of this research, supported by an Australian $3.1M AusIndustry START grant, is focused towards building the company's future internal drug pipeline and in house efforts are augmented by collaboration with Martin Banwell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2005-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry